| JERSX | MGLCX | JERSX / MGLCX | |
| Total Expense Ratio | 1.16 | 1.94 | 60% |
| Annual Report Gross Expense Ratio | 1.16 | 1.95 | 59% |
| Fund Existence | 18 years | 11 years | - |
| Gain YTD | 3.094 | 1.916 | 161% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2500 | 1000 | 250% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 312M | 2.22B | 14% |
| Annual Yield % from dividends | 2.90 | 2.05 | 141% |
| Returns for 1 year | 15.59 | 7.14 | 218% |
| Returns for 3 years | 13.53 | 4.36 | 310% |
| Returns for 5 years | 7.70 | -1.60 | -480% |
| Returns for 10 years | 72.73 | 29.37 | 248% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FTDZX | 177.87 | 3.90 | +2.24% |
| Franklin Biotechnology Discovery Adv | |||
| MMMSX | 23.66 | 0.11 | +0.47% |
| Victory Integrity Small/Mid-Cap Value Mb | |||
| GEMCX | 26.24 | 0.02 | +0.08% |
| Goldman Sachs Emerging Markets Eq C | |||
| ASIRX | 12.56 | N/A | N/A |
| Alger Small Cap Growth Institutional R | |||
| JDCRX | 43.19 | -0.58 | -1.33% |
| Janus Henderson Forty R | |||